Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy

References

• Stanisic S, Kalaycio M. Treatment of refractory and relapsed acute myelogenous leukemia. Expert Rev Anticancer Ther 2002;2:287–295.
   PubMedGoogle Scholar
• Davis CL, Rohatiner AZS, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA. The management of recurrent acute myelogenous leukemia at a single center over a fifteen-year period. Br J Haematol 1993;83:404–411.
   Google Scholar
• Clift RA, Buckner CD, Thomas ED, Kopecky KJ, Appelbaum FR, Tallman M, Storb R, Sanders J, Sullivan K, Banaji M. The treatment of acute nonlymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 1987;2:243–258.
   PubMed Web of Science ®Google Scholar
• Gorki N, Labopin M, Meloni G, Korbling M, Carella A, Herve P, Burnett A, Rizzoli V, Alessandrino EP, Bjorkstrand B. Autologous bone marrow transplantation for acute myelo-blastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. Leukemia 1991;5:896–904.
   PubMed Web of Science ®Google Scholar
• Chopra R, Goldstone AH, McMillan AK. Successful treat-ment of acute myeloid leukemia beyond first remission with autologous bone marrow transplantation using busul-fan/cyclophosphamide and unpurged marrow: the British Autograft Group experience. J Chin Oncol 1991;9:1840–1847.
   Google Scholar
• Meloni G, De Fabritiis P, Petti MC, Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remis-sion. Blood 1990;75:2282–2285.
   PubMed Web of Science ®Google Scholar
• Tomas F, Gomez-Garcia de Soria V, Lopez-Lorenzo JL, Arranz R, Figuera A, Camara R, Alegre A, Fernandez-Ranada JM. Autologous or allogeneic bone marrow transplantation for acute myeloblastic leukemia in second complete remission: importance of duration of first complete remission in final outcome. Bone Marrow Transplant 1996;17:979–984.
   Google Scholar
• Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL. Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant 2002;29:297–301.
   PubMed Web of Science ®Google Scholar
• Archimbaud E, Thomas X, Leblond V, Michallet M, Fenaux P, Cordonnier C, Dreyfus F, Troussard X, Jaubert J, Travade P. Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Chin Oncol 1995;13:11–18.
   PubMed Web of Science ®Google Scholar
• Burke PJ, Vaughan WP, Karp JE. A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation. Blood 1980;55:960–968.
   Google Scholar
• Vaughan WP, Karp JE, Burke PJ. Long chemotherapy-free remissions after single-cycle timed sequential chemotherapy for acute myelocytic leukemia. Cancer 1980;45:859–865.
   Google Scholar
• Vaughan WP, Karp JE, Burke PJ. Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 1984;64:975–980.
   Google Scholar
• Fiere D, Campos L, Vu Van H, Guyotat D, Archimbaud E, Extra JM, Coiffer B, Viala JJ, Bryon PA, Milan II. Intensive timed chemotherapy protocol for 37 resistant or relapsing acute myeloid leukemias. Cancer Treat Rep 1986;70:285–286.
   PubMedGoogle Scholar
• Archimbaud E, Leblond V, Michallet M, Cordonnier C, Fenaux P, Travade P, Dreyfus F, Jaubert J, Devaux Y, Fiere D. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for resistant or relapsing acute myelogenous leukemia. Blood 1991;77:1894–1900.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American- British Cooperative Group. Ann Intern Med 1985;103:626–629.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Criteria for the diagnosis of acute leukemia of megacaryocyte lineage (M7). A report from the French-American-British Cooperative Group. Ann Intern Med 1985;103: 460–462.
   Google Scholar
• Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol 1991;78: 325–329.
   Google Scholar
• World Health Organization. Handbook for reporting results of cancer treatment. WHO offset publication 48. Geneva: WHO; 1979.
   Google Scholar
• Archimbaud E, Fenaux P, Reiffers J, Cordonnier C, Leblond V, Travade P, Troussand X, Tilly H, Auzanneau G, Marie JP. Granulocyte-macrophage colony-stimulating factor in associa-tion to timed-sequential chemotherapy with mitoxantrone, etoposide and cytarabine for refractory acute myelogenous leukemia. Leukemia 1993;7:372–373.
   PubMed Web of Science ®Google Scholar
• Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H, Vekhoff A, Cony-Makhoul P, Leblond V, Troussard X. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 trial). Leukemia 1999;13: 1214–1220.
   Google Scholar
• Thomas X, Dombret H, Cordonnier C, Pigneux A, Gardin C, Guerci A, Vekhoff A, Sadoun A, Stamatoullas A, Fegueux N. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic therapy followed by timed sequential che-motherapy and stem cell transplantation. Leukemia 2000;14:1006–1013.
   PubMed Web of Science ®Google Scholar
• Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J, Sawitsky A, Rosner F, Gussoff B, Silver RT. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968;32:507–523.
   PubMed Web of Science ®Google Scholar
• Preisler HD. Failure of remission induction in acute myelo-cytic leukemia. Med Ped Oncol 1978;4:275–276.
   PubMedGoogle Scholar
• Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG, Wheatley K. Randomised comparison of addition of autologous bone-marrow transplantation to intensive che-motherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998;351: 700–708.
   Google Scholar
• Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998;339:1649–1656.
   PubMed Web of Science ®Google Scholar
• Zittoun RA, Mandelli F, Willemze R, De Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G. Autologous or allogeneic bone marrow transplantation com-pared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 1995;332:217–223.
   Google Scholar
• Harousseau JL, Calm JY, Pignon B, Witz F, Milpied N, Delain M Lioure B, Lamy T, Desablens B, Guilhot F. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997;90:2978–2986.
   Google Scholar
• Grigg AP, Szer J, Berestord J, Dodds A, Bradstock K, Durrant S, Schwarer AP, Hughes T, Hermann R, Gibson J. Factors affecting the outcome of allogeneic bone marrow transplanta-tion for adult patients with refractory or relapsed acute leukaemia. Br J Haematol 1999;107:409–418.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 200198:1752-1759.
   PubMed Web of Science ®Google Scholar
• Byrne JL, Dasgupta E, Pallis M, Turzanski J, Forman K, Mitchell D, Haynes AP, Russell NH. Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG. Leukemia 1999;13:786–791.
   PubMed Web of Science ®Google Scholar
• Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR, Dusenbery K, DeSwarte J, Arthur DC, Lange BJ. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children's Cancer Group. Blood 2001;97:56–62.
   PubMed Web of Science ®Google Scholar
• Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, Kim KM, Zhang MJ, Ash RC, Atkinson K. Chemother-apy versus transplants for acute myelogenous leukemia in second remission. Leukemia 1996;10:13–19.
   PubMed Web of Science ®Google Scholar
• Forman SJ, Schmidt GM, Nademanee AP, Amylon MB, Chao NJ, Fahey JL, Konrad PN, Margolin KA, Niland JC, O'Donnell MR. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia. J Chin Oncol 1991;9:1570–1574.
   Google Scholar
• De Botton S, Fawaz A, Chevret S, Thomas X, Dombret H, Sanz M, Guerci A, San Miguel J, de la Serna J, Stoppa AM. Autologous and allogeneic stem cell trans-plantation (SCT) in second CR (CR2) in acute promyelo-cytic leukemia (APL) initially treated with ATRA: European APL Group experi-ence. Blood 2002;100:217a.
   Google Scholar
• Meloni G, Vignetti M, Avvisatti G, Capria S, Micozzi A, Giona F, Mandelli F. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission. Bone Marrow Transplant 1996;18:693–698.
   Google Scholar
• Gorin NC. Autologous stem cell transplantation in acute myelocytic leukemia. Blood 1998;92:1073–1090.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Labopin M, Fouillard L, Meloni G, Frassoni F, Iriondo A, Brunet Mauri S, Goldstone AM, Marousseau JL, Reiffers J. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplan-tation from an HLA identical related donor in acute myelocytic leukemia. Bone Marrow Transplant 1996;18: 111–117.
   PubMed Web of Science ®Google Scholar
• Sanz M, de la Rubia J, Sanz GF, Martin G, Martinez J, Jarque I, Sempere A, Gomis F, Senent L, Soler MA. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. J Chin Oncol 1993;11:1661–1667.
   PubMed Web of Science ®Google Scholar
• Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR Jr, Hertenstein B. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplanta-tion. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000;95:3702–3709.
   Google Scholar
• Korbling M, Fliedner TM, Holle R, Magrin S, Baumann M, Holdermann E, Eberhardt K. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991;7:343–349.
   Google Scholar
• Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, Braine HG, Burke PJ, Ambinder RF, Burns WH. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986;315:141–147.
   PubMed Web of Science ®Google Scholar
• Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A, Carella A, Korbling M, Herve P, Maraninchi D. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging. Blood 1990;75:1606–1614.
   PubMed Web of Science ®Google Scholar
• Demirer T, Gooley T, Buckner CD, Petersen FB, Lilleby K, Rowley S, Saunders J, Storb R, Appelbaum FR, Bessinger WI. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia under-going autologous transplantation. Bone Marrow Transplant 1995;15:907–913.
   PubMed Web of Science ®Google Scholar
• Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Chin Oncol 2001;19:3852–3860.
   PubMed Web of Science ®Google Scholar